View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 05, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	TRXC
Entity Registrant Name	TRANSENTERIX INC.
Entity Central Index Key	0000876378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		148,529,689

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenue	$ 1,946
Cost of revenue	1,334
Gross profit	612
Operating Expenses
Research and development	6,855	$ 8,385
Sales and marketing	3,723	1,683
General and administrative	3,049	2,239
Amortization of intangible assets	1,636	1,817
Change in fair value of contingent consideration	1,227	856
Total Operating Expenses	16,490	14,980
Operating Loss	(15,878)	(14,980)
Other Expense
Interest expense, net	(334)	(578)
Other income	(60)
Total Other Expense, net	(394)	(578)
Loss before income taxes	(16,272)	(15,558)
Income tax benefit	858	2,645
Net loss	(15,414)	(12,913)
Other comprehensive gain
Foreign currency translation loss	1,133	3,796
Comprehensive loss	$ (14,281)	$ (9,117)
Net loss per share - basic and diluted	$ (0.13)	$ (0.12)
Weighted average common shares outstanding - basic and diluted	121,660	104,260

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 13,086	$ 24,165
Accounts receivable, net	1,828	621
Inventories	8,321	7,883
Interest receivable	10	12
Other current assets	5,601	5,335
Total Current Assets	28,846	38,016
Restricted cash	10,432	10,425
Accounts receivable, net of current portion		266
Property and equipment, net	5,800	5,772
Intellectual property, net	36,015	37,090
In-process research and development	16,161	15,920
Goodwill	68,984	68,697
Other long term assets	114	63
Total Assets	166,352	176,249
Current Liabilities
Accounts payable	3,269	3,984
Accrued expenses	7,262	8,206
Contingent consideration – current portion	6,250	10,502
Notes payable - current portion, net of debt discount	8,172	7,997
Total Current Liabilities	24,953	30,689
Long Term Liabilities
Contingent consideration – less current portion	12,550	12,298
Notes payable - less current portion, net of debt discount	2,885	4,995
Net deferred tax liabilities	9,697	10,397
Total Liabilities	50,085	58,379
Commitments and Contingencies
Stockholders’ Equity
Common stock $0.001 par value, 750,000,000 shares authorized at March 31, 2017, and December 31, 2016; 123,629,689 and 115,781,030 shares issued at March 31, 2017 and December 31, 2016, respectively; and 123,629,689 and 115,687,351 shares outstanding at March 31, 2017 and December 31, 2016, respectively	123	115
Additional paid-in capital	439,038	426,609
Accumulated deficit	(318,258)	(302,844)
Treasury stock at cost, 0 and 93,679 shares at March 31, 2017 and December 31, 2016, respectively		(241)
Accumulated other comprehensive loss	(4,636)	(5,769)
Total Stockholders’ Equity	116,267	117,870
Total Liabilities and Stockholders’ Equity	$ 166,352	$ 176,249

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Partners Capital [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	123,629,689	115,781,030
Common stock, shares outstanding	123,629,689	115,687,351
Treasury stock, shares	0	93,679

Consolidated Statements of Shareholders' Equity (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2016	$ 117,870	$ 115	$ (241)	$ 426,609	$ (302,844)	$ (5,769)
Balance, Shares at Dec. 31, 2016		115,781	(94)
Stock-based compensation	2,139			2,139
Issuance of common stock and treasury stock, net of issuance costs	5,478	$ 4	$ 407	5,067
Issuance of common stock and treasury stock, net of issuance costs, Shares		3,795	211
Award of restricted stock units, Shares		331
Return of common stock to pay withholding taxes on restricted stock	(166)		$ (166)
Return of common stock to pay withholding taxes on restricted stock, Shares			(117)
Issuance of common stock in exchange for contingent consideration	5,227	$ 4		5,223
Issuance of common stock in exchange for contingent consideration, Shares		3,723
Other comprehensive gain	1,133					1,133
Net loss	(15,414)				(15,414)
Balance at Mar. 31, 2017	$ 116,267	$ 123		$ 439,038	$ (318,258)	$ (4,636)
Balance, Shares at Mar. 31, 2017		123,630

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Operating Activities
Net loss	$ (15,414)	$ (12,913)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation	532	565
Amortization of intangible assets	1,636	1,817
Amortization of debt discount and debt issuance costs	31	52
Stock-based compensation	2,139	1,428
Deferred tax benefit	(858)	(2,645)
Change in fair value of contingent consideration	1,227	856
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable	(753)
Interest receivable	2	(6)
Inventories	(320)	(1,735)
Other current and long term assets	(251)	(132)
Accounts payable	(759)	(1,391)
Accrued expenses	(1,161)	(765)
Net cash and cash equivalents used in operating activities	(13,949)	(14,869)
Investing Activities
Purchase of property and equipment	(501)	(153)
Net cash and cash equivalents (used in) provided by investing activities	(501)	(153)
Financing Activities
Payment of debt	(1,966)	(1,219)
Proceeds from issuance of common stock, net of issuance costs	5,304	31,391
Taxes paid related to net share settlement of vesting of restricted stock units		(130)
Proceeds from exercise of stock options and warrants		8
Net cash and cash equivalents provided by financing activities	3,338	30,050
Effect of exchange rate changes on cash and cash equivalents	40	34
Net (decrease) increase in cash, cash equivalents and restricted cash	(11,072)	15,062
Cash, cash equivalents and restricted cash, beginning of period	34,590	38,449	$ 38,449
Cash, cash equivalents and restricted cash, end of period	23,518	53,511	$ 34,590
Supplemental Disclosure for Cash Flow Information
Interest paid	233	373
Supplemental Schedule of Noncash Investing Activities
Transfer of inventory to property and equipment		$ 1,823
Issuance of common stock as contingent consideration	$ 5,227

Organization and Capitalization	3 Months Ended
Organization and Capitalization	Mar. 31, 2017
Accounting Policies [Abstract]
Organization and Capitalization	1. Organization and Capitalization TransEnterix, Inc. (the “Company”) is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical challenges associated with current laparoscopic and robotic options. The Company is focused on the commercialization and further development of its Senhance™ Surgical Robotic System (formerly known as the ALF-X ® Surgical Robotic System) (the “Senhance System”), a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology. The Company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, but is not available for sale in the U.S. The SurgiBot System is not available for sale in any market. The Senhance System is a multi-port robotic surgery system which allows multiple arms to control robotic instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera via eye movement. The system replicates laparoscopic motion that is familiar to experienced surgeons, and features three-dimensional high definition (“3DHD”) vision technology. The Senhance System also offers responsible economics to hospitals by offering robotic technology with reusable instruments with minimal additional costs per surgery. In April 2017, the Company submitted a 510(k) application to the Food and Drug Administration, or FDA, for the Senhance System. The SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon, with robotic assistance, while the surgeon remains patient-side within the sterile field. In June 2015, the Company submitted a 510(k) application to the FDA for the SurgiBot System. On April 19, 2016, the FDA notified the Company that the SurgiBot System did not meet the criteria for substantial equivalence based on the data and information submitted by TransEnterix in the 510(k) submission. In May 2016, the Company implemented a restructuring plan. See Note 13 to the consolidated financial statements for further details regarding the restructuring. On September 3, 2013, TransEnterix Surgical, Inc. a Delaware corporation (“TransEnterix Surgical”), and SafeStitch Medical, Inc., a Delaware corporation (“SafeStitch”) consummated a merger transaction whereby TransEnterix Surgical merged with a merger subsidiary of SafeStitch, with TransEnterix Surgical as the surviving entity in the merger (the “Merger”). As a result of the Merger, TransEnterix Surgical became a wholly owned subsidiary of SafeStitch. On December 6, 2013, SafeStitch changed its name to TransEnterix, Inc. and increased the authorized shares of common stock from 225,000,000 to 750,000,000, and authorized 25,000,000 shares of preferred stock, par value $0.01 per share. On September 18, 2015, the Company entered into a Membership Interest Purchase Agreement, (the “Purchase Agreement”) with Sofar S.p.A., (“Sofar”) as seller, Vulcanos S.r.l. (“Vulcanos”), as the acquired company, and TransEnterix International, Inc. (“TransEnterix International”), a direct, wholly owned subsidiary of the Company which was incorporated in September 2015, as buyer. The closing of the transactions occurred on September 21, 2015 (the “Closing Date”) pursuant to which the Company acquired all of the membership interests of Vulcanos from Sofar (now known as the “Senhance Acquisition”), and changed the name of Vulcanos to TransEnterix Italia S.r.l (“TransEnterix Italia”). The Senhance Acquisition included all of the assets, employees and contracts related to the Senhance System. See Note 3 for a description of the related transactions. As used herein, the term “Company” refers to the combination of SafeStitch and TransEnterix Surgical after giving effect to the Merger, and includes TransEnterix International, TransEnterix Italia, TransEnterix Europe S.Á.R.L, TransEnterix Europe S.Á.R.L, Bertrange, Swiss Branch, Lugano and TransEnterix Asia PTE. LTD. after giving effect to the Senhance Acquisition. The Company operates in one business segment.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company has prepared the accompanying unaudited interim condensed consolidated financial statements in accordance with the instructions to Form 10-Q and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Consequently, the Company has not necessarily included in this Form 10-Q all information and footnotes required for audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements in this Form 10-Q contain all adjustments, consisting only of normal recurring adjustments, except as otherwise indicated, necessary for a fair statement of its financial position, results of operations, and cash flows of the Company for all periods presented. The results reported in these condensed consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for any subsequent period or for the entire year. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and the notes thereto included in the Company’s latest Annual Report on Form 10-K. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in the accompanying interim consolidated financial statements. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying Consolidated Financial Statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, SafeStitch LLC, TransEnterix Surgical, Inc., TransEnterix International, Inc., TransEnterix Italia S.r.l., TransEnterix Europe S.Á.R.L, TransEnterix Europe S.Á.R.L, Bertrange, Swiss Branch, Lugano and TransEnterix Asia PTE. LTD. All inter-company accounts and transactions have been eliminated in consolidation.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis. The Company has accumulated a deficit of approximately $318.3 million as of March 31, 2017, and has not generated significant revenue or positive cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and other funding transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. If the Company is unable to obtain the necessary capital, it will need to pursue a plan to license or sell its assets, seek to be acquired by another entity and/or cease operations.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include identifiable intangible assets and goodwill, contingent consideration, stock compensation expense, restructuring and other charges, excess and obsolete inventory reserves, and deferred tax asset valuation allowances.

Cash and Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents and investments with original maturities of between 91 days and one year to be short-term investments. In order to manage exposure to credit risk, the Company invests in high-quality investments rated at least A2 by Moody’s Investors Service or A by Standard & Poor.

Restricted cash at March 31, 2017 includes $10.0 million in a money market account, held in connection with the Company’s notes payable and $432,000 in cash accounts held as collateral primarily under the terms of an office operating lease and automobile leases.

Fair Value of Financial Instruments

The carrying values of accounts receivable, interest receivable, accounts payable, and certain accrued expenses at March 31, 2017 and December 31, 2016, approximate their fair values due to the short-term nature of these items. The Company’s notes payable balance also approximates fair value as of March 31, 2017 and December 31, 2016, as the interest rates on the notes payable approximate the rates available to the Company as of these dates.

2. Summary of Significant Accounting Policies (Continued)

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents and investments held in money market accounts. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s cash deposits may at times exceed the FDIC insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts.

The Company’s accounts receivable are derived from net revenue to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date. The Company had three customers who constituted 100% of the Company’s net accounts receivable at March 31, 2017 and one customer who constituted 100% of the Company’s net accounts receivable at December 31, 2016.

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for estimated uncollectable accounts. The allowance for uncollectible accounts was determined based on historical collection experience.

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) and net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Any inventory on hand at the measurement date in excess of the Company’s current requirements based on anticipated levels of sales is classified as long-term on the Company’s consolidated balance sheets.

Identifiable Intangible Assets and Goodwill

Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain intangible assets are amortized over 7 to 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Developed research and development was acquired as part of a business acquisition. Amortization of the developed research and development is recorded using the straight-line method over the estimated useful life of 7 years. This method approximates the period over which the Company expects to receive the benefit from these assets. No impairment existed at March 31, 2017 or December 31, 2016.

Indefinite-lived intangible assets, such as goodwill, are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis at December 31 or when events or changes in circumstances indicate evidence a potential impairment exists, using a fair value based test. The Company continues to operate in one segment, which is considered to be the sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. See Note 13 for additional information related to goodwill impairment recorded during the second quarter of 2016. No impairment existed at March 31, 2017.

2. Summary of Significant Accounting Policies (Continued)

In-Process Research and Development

In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that were acquired, which at the time of acquisition have not reached technological feasibility and have no alternative future use. IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. During the period that the IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value. The IPR&D was acquired on September 21, 2015. No impairment existed at March 31, 2017 and December 31, 2016.

Property and Equipment

Property and equipment consists primarily of machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost.

Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

Machinery, manufacturing and demonstration equipment		3-5 years
Computer equipment		3 years
Furniture		5 years
Leasehold improvements		Lesser of lease term or 3 to 10 years

Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.

Impairment of Long-Lived Assets

The Company reviews its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value. The Company’s estimates of anticipated cash flows and the remaining estimated useful lives of long-lived assets could be reduced in the future, resulting in a reduction to the carrying amount of long-lived assets.

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration at each reporting date is updated by reflecting the changes in fair value in our statement of operations and comprehensive loss.

Translation of Foreign Currencies

The functional currency of the Company’s operational foreign subsidiaries is Euros. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive income or loss as a separate component of stockholders’ equity.

2. Summary of Significant Accounting Policies (Continued)

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statement of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the three months ended March 31, 2017 and 2016 were not significant.

Risk and Uncertainties

The Company is subject to a number of risks similar to other similarly-sized companies in the medical device industry. These risks include, without limitation, the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully integrate the Senhance System into its business; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the health care and regulatory environments of the United States, Italy, other countries in the European Union, and other countries in which the Company intends to operate; its ability to attract and retain key management, marketing and scientific personnel; competition from new entrants; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution concern; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sales of systems, instruments and accessories, and service revenue. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue is presented net of taxes collected from customers that are remitted to government authorities. The Company generally recognizes revenue at the following points in time:

•

System sales. For systems sold directly to end customers, revenue is recognized when acceptance occurs, which is deemed to have occurred upon customer acknowledgment of delivery or installation, depending on the terms of the arrangement. The Senhance Systems are delivered with a software component. However, because the software and non-software elements function together to deliver the system’s essential functionality, the Company's arrangements are excluded from being accounted for under software revenue recognition guidance.

•

Instruments and accessories. Revenue from sales of instruments and accessories is generally recognized at the time of shipment.

•

Service. Service revenue is recognized ratably over the term of the service period. Revenue related to services performed on a time-and-materials basis is recognized when it is earned and billable.

The Company's system sale arrangements contain multiple elements including a system(s), instruments, accessories, and system service. The Company generally delivers all of the elements, other than service, within days of entering into the system sale arrangement. Each of these elements is a separate unit of accounting. System accessories, instruments, and service are also sold on a stand-alone basis.

For multiple-element arrangements, revenue is allocated to each unit of accounting based on their relative selling prices. Relative selling prices are based first on vendor specific objective evidence of fair value (“VSOE”), then on third-party evidence of selling price (“TPE”) when VSOE does not exist, and then on management's best estimate of the selling price (“BESP”) when VSOE and TPE do not exist.

The Company’s system sale arrangements generally include a one-year period of free service, and the right for the customer to purchase service annually thereafter. The revenue allocated to the free service period is deferred and recognized ratably over the free service period.

2. Summary of Significant Accounting Policies (Continued)

Because the Company has neither VSOE nor TPE for its systems, the allocation of revenue is based on BESP for the systems sold. The objective of BESP is to determine the price at which the Company would transact a sale, had the product been sold on a stand-alone basis. The Company determines BESP for its systems by considering multiple factors, including, but not limited to, features and functionality of the system, geographies, type of customer, and market conditions. The Company regularly reviews BESP and maintains internal controls over establishing and updating these estimates.

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.

Stock-Based Compensation

The Company follows ASC 718 (“Stock Compensation”) and ASC 505-50 (“Equity-Based Payments to Non-employees”), which provide guidance in accounting for share-based awards exchanged for services rendered and requires companies to expense the estimated fair value of these awards over the requisite service period. For awards granted to non-employees, the Company determines the fair value of the stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.

The Company recognizes compensation expense for stock-based awards based on estimated fair values on the date of grant for awards granted to employees. The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. The expense associated with stock-based compensation is recognized on a straight-line basis over the requisite service period of each award.

The Company records as expense the fair value of stock-based compensation awards, including stock options and restricted stock units. Compensation expense for stock-based compensation was approximately $2,139,000 and $1,428,000 for the three months ended March 31, 2017 and 2016, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized.

2. Summary of Significant Accounting Policies (Continued)

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 44% of the Company’s total consolidated assets are located within the U.S. as of March 31, 2017. The remaining assets are mostly located in Europe and are primarily related to the Company’s facility in Italy, and include goodwill, intellectual property, in-process research and development, other current assets, property and equipment, cash, accounts receivable and inventory of $92.6 million at March 31, 2017, associated with the Senhance Acquisition in September 2015. Total assets outside of the U.S. excluding goodwill amounted to 44% and 40% of total consolidated assets at March 31, 2017 and December 31, 2016, respectively.

Impact of Recently Issued Accounting Standards

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This ASU is effective prospectively to annual and interim impairment tests beginning after December 15, 2019, with early adoption permitted. The Company early adopted this ASU as of the beginning of fiscal year 2017. The adoption of this ASU did not have a material impact on the consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) which addresses changes to reduce the presentation diversity of certain cash receipts and cash payments in the statement of cash flows, including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, and distributions received from equity method investees. The guidance becomes effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The new standard will be applied retrospectively, but may be applied prospectively if retrospective application would be impracticable. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated statement of cash flows.

In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting. Under ASU 2016-09, the tax effects of stock compensation will be recognized as income tax expense or benefit in the income statement and the tax effects of exercised or vested awards will be treated as discrete items in the reporting period in which they occur. Along with other income tax cash flows, excess tax benefits will be classified as operating activities, and cash paid by an employer when directly withholding shares for tax withholding purposes will be classified as financing activities. Entities may make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. The threshold to qualify for equity classification permits withholding up to the maximum statutory tax rates in the applicable jurisdictions. For public companies, ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted this ASU as of the beginning of fiscal year 2017 and did not elect to account for forfeitures when they occur, but will continue to estimate the number of awards that are expected to vest. The adoption of this ASU did not have a material impact on the consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company currently expects that upon adoption, ROU assets and lease liabilities will be recognized in the balance sheet in amounts that the Company does not expect will have a material impact on the consolidated financial statements based on the Company’s current leases.

2. Summary of Significant Accounting Policies (Continued)

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The updated guidance is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). Due to limited sales, the Company has evaluated its contracts and has concluded that the impact of adopting the standard will have no material impact on its consolidated financial statements and related disclosures.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330). This update requires inventory within the scope of the standard to be measured at the lower of cost and net realizable value. Previous guidance required inventory to be measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). This update is effective for annual and interim periods beginning after December 15, 2016. The Company adopted these provisions in the first quarter of fiscal year 2017 with no material impact on its consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements or related footnote disclosures.

Except as noted above, there have been no significant changes to our assessment of the impact of recently issued accounting standards included in Note 2 of Notes to Consolidated Financial Statements in our Fiscal 2016 Form 10-K.

Acquisition of Senhance Surgical Robotic System	3 Months Ended
Acquisition of Senhance Surgical Robotic System	Mar. 31, 2017
Business Combinations [Abstract]
Acquisition of Senhance Surgical Robotic System	3. Acquisition of Senhance Surgical Robotic System On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System and changed the name of the acquired company from Vulcanos S.r.l. to TransEnterix Italia S.r.l. 3. Acquisition of Senhance Surgical Robotic System (Continued) Under the terms of the Purchase Agreement, the consideration consisted of the issuance of 15,543,413 shares of the Company’s common stock (the “Securities Consideration”) and approximately $25.0 million U.S. Dollars and €27.5 million Euro in cash consideration (the “Cash Consideration”). The Securities Consideration was issued in full at the closing of the Senhance Acquisition; the Cash Consideration was or will be paid in four tranches, as follows: (1) $25.0 million of the Cash Consideration was paid at closing; (2) On December 30, 2016, the Company entered into an Amendment to the Purchase Agreement (the “Amendment”) to restructure the terms of the second tranche of the Cash Consideration (the “Second Tranche”). Under the Amendment, the Second Tranche was restructured to be paid through the (A) the issuance of 3,722,685 shares of the Company’s common stock with an aggregate fair market value of €5.0 million and (B) the payment of €5.0 million in cash upon the occurrence of either (i) receipt of clearance from the FDA for the Senhance System; or (ii) the Company having cash on hand of at least $50.0 million, or (iii) successfully completing a financing, raising at least $50.0 million in gross proceeds after September 2015, exclusive of any financing proceeds related to the December 2016 purchase agreement between the Company and Lincoln Park Capital Fund, LLC.; with payment of simple interest at a rate of 9.0% per annum beginning on December 31, 2016. Prior to December 30, 2016, the second tranche of the Cash Consideration of €10.0 million was payable after the achievement of both of the following milestones (i) the earlier of approval from the FDA for the Senhance System or December 31, 2016, and (ii) the Company having cash on hand of at least $50.0 million, or successfully completing a financing, raising at least $50.0 million in gross proceeds; with payment of simple interest at a rate of 9.0% per annum between the achievement of the first milestone event and the payment date. (3) The third tranche of the Cash Consideration (the “Third Tranche”) of €15.0 million shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter. (4) The fourth tranche of the Cash Consideration of €2.5 million shall be payable by December 31 of each year as reimbursement for certain debt payments made by Sofar under an existing Sofar loan agreement in such year, with payments beginning as of December 31, 2016. As of March 31, 2017 and December 31, 2016, the Company had paid €1.1 million of the fourth tranche. The Third Tranche will be payable even if the Second Tranche is not then payable. In addition, the Second Tranche and Third Tranche payments will be accelerated in the event that (i) the Company or TransEnterix International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. Under the Purchase Agreement, 10% of the Securities Consideration was being held in escrow to support Sofar’s representations and warranties under the Purchase Agreement. In accordance with a related escrow agreement, the escrowed shares were released in September 2016. The Company, a subsidiary and Sofar also entered into a Security Agreement, which provides that 10% of the membership interests of TransEnterix Italia have a lien placed thereon by and in favor of Sofar to support the Company’s representations and warranties under the Purchase Agreement. The security interest period is twenty-four months after the closing of the Senhance Acquisition. The Purchase Agreement contains customary representations and warranties of the parties and the parties have customary indemnification obligations, which are subject to certain limitations described further in the Purchase Agreement. In connection with the Senhance Acquisition, the Company also entered into a Registration Rights Agreement, dated as of September 21, 2015, with Sofar, pursuant to which the Company agreed to register the Securities Consideration shares for resale following the end of the lock-up periods described below. The resale registration statement has been filed and is effective, pending lapse of the lock-up restrictions as described below. 3. Acquisition of Senhance Surgical Robotic System (Continued) In connection with the Senhance Acquisition, Sofar entered into a Lock-Up Agreement with the Company pursuant to which Sofar agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Securities Consideration for one year following the Closing Date. As of March 21, 2017, seventy-five percent of the Securities Consideration was released from the lock-up restrictions and is eligible to be resold under the effective resale registration statement. With respect to the remaining twenty-five percent of the Securities Consideration, it remains locked-up until the two-year anniversary of the Closing Date. The restrictions on transfer contained in the Lock-up Agreement cease to apply to all of the Securities Consideration following the second anniversary of the Closing Date, or earlier upon certain other conditions. The Senhance Acquisition was accounted for as a business combination utilizing the methodology prescribed in ASC 805. The purchase price for the Senhance Acquisition was allocated to the assets acquired and liabilities assumed based on their estimated fair values.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Fair Value

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value

4. Fair Value

The Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis. These assets and liabilities include available for sale securities classified as cash and cash equivalents, restricted cash and contingent consideration. ASC 820-10 (“Fair Value Measurement Disclosure”) requires the valuation using a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.

For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and therefore, are based primarily upon estimates, are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.

As prescribed by U.S. GAAP, the Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy.

The determination of where an asset or liability falls in the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures and based on various factors, it is possible that an asset or liability may be classified differently from period to period. However, the Company expects changes in classifications between levels will be rare.

4. Fair Value (Continued)

The following are the major categories of assets measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016, using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

	March 31, 2017
	(In thousands)
	(unaudited)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	13,086	$	—	$	—	$	13,086
Restricted cash		10,432		—		—		10,432
Total Assets measured at fair value	$	23,518	$	—	$	—	$	23,518
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	18,800	$	18,800
Total liabilities measured at fair value	$	—	$	—	$	18,800	$	18,800

	December 31, 2016
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	24,165	$	—	$	—	$	24,165
Restricted cash		10,425		—		—		10,425
Total Assets measured at fair value	$	34,590	$	—	$	—	$	34,590
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	22,800	$	22,800
Total liabilities measured at fair value	$	—	$	—	$	22,800	$	22,800

The Company’s financial liabilities consisted of contingent consideration potentially payable to Sofar related to the Senhance Acquisition in September 2015 (Note 3). This liability is reported as Level 3 as estimated fair value of the contingent consideration related to the acquisition requires significant management judgment or estimation and is calculated using the income approach, using various revenue and cost assumptions and applying a probability to each outcome. The change in fair value of the contingent consideration of $1,227,000 and $856,000 for the three months ended March 31, 2017 and 2016, respectively, was primarily due to the effect of the passage of time on the fair value measurement and the impact of foreign currency exchange rates. Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of December 31, 2016 and March 31, 2017:

Valuation

Methodology

Significant

Unobservable Input

Weighted Average

(range, if

applicable)

Contingent consideration

Probability weighted

income approach

Milestone dates

2016 to 2017

Discount rate

Probability of occurrence

7.5% to 9.0%

100%

4. Fair Value (Continued)

The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs for the three months ended March 31, 2017:

	Fair Value Measurement at Reporting Date (Level 3)
	(In thousands)
	(unaudited)
Balance at December 31, 2016	$	22,800
Conversion of contingent consideration to common stock		(5,227	)
Change in fair value		1,227
Balance at March 31, 2017	$	18,800
Current portion		6,250
Long-term portion		12,550
Balance at March 31, 2017	$	18,800

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accounts Receivable, Net

3 Months Ended

Mar. 31, 2017

Receivables [Abstract]

Accounts Receivable, Net

5. Accounts Receivable, Net

The following table presents the components of accounts receivable:

	March 31,			December 31,
	2017			2016
	(In thousands)
Gross accounts receivable	$	1,901		$	960
Allowance for uncollectible accounts		(73	)		(73	)
Total accounts receivable, net	$	1,828		$	887
Short-term portion	$	1,828		$	621
Long-term portion		—			266
Total accounts receivable	$	1,828		$	887

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories

6. Inventories

The components of inventories are as follows:

	March 31,		December 31,
	2017		2016
	(In thousands)
Finished goods	$	3,359	$	4,698
Raw materials		4,962		3,185
Total inventories	$	8,321	$	7,883

Other Current Assets

3 Months Ended

Mar. 31, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

7. Other Current Assets

The following table presents the components of other current assets:

	March 31,		December 31,
	2017		2016
	(In thousands)
Prepaid expenses	$	1,118	$	2,186
Advances to vendors		3,967		1,806
Other receivables		516		1,343
Total	$	5,601	$	5,335

Property and Equipment

3 Months Ended

Mar. 31, 2017

Property Plant And Equipment [Abstract]

Property and Equipment

8. Property and Equipment

Property and equipment consisted of the following:

	March 31,			December 31,
	2017			2016
	(In thousands)
Machinery, manufacturing and demonstration equipment	$	8,088		$	7,579
Computer equipment		2,134			2,124
Furniture		624			614
Leasehold improvements		2,067			2,028
Total property and equipment		12,913			12,345
Accumulated depreciation and amortization		(7,113	)		(6,573	)
Property and equipment, net	$	5,800		$	5,772

Depreciation expense was $532,000 and $565,000 for the three months ended March 31, 2017 and 2016, respectively.

Goodwill, In-Process Research and Development and Intellectual Property

3 Months Ended

Mar. 31, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill, In-Process Research and Development and Intellectual Property

9. Goodwill, In-Process Research and Development and Intellectual Property

Goodwill

Goodwill of $93.8 million was recorded in connection with the Merger, as described in Note 1, and goodwill of $38.3 million was recorded in connection with the Senhance Acquisition, as described in Note 3. The carrying value of goodwill and the change in the balance for the three months ended March 31, 2017 is as follows:

	Goodwill
	(In thousands)
Balance at December 31, 2016	$	68,697
Foreign currency translation impact		287
Balance at March 31, 2017	$	68,984

The Company performs an annual impairment test of goodwill at December 31, or more frequently if events or changes in circumstances indicates that the carrying value of the Company’s one reporting unit may not be recoverable. During the second quarter of 2016, the FDA notified the Company that the SurgiBot System did not meet the criteria for substantial equivalency, negatively impacting the Company’s market capitalization, and warranting an interim two-step quantitative impairment test. Prior to adopting ASU 2017-04 as of the beginning of fiscal year 2017, goodwill was tested for impairment using a two-step approach. In the first step, the fair value of the reporting unit was determined and compared to the reporting unit's carrying value, including goodwill. If the fair value of the reporting unit was less than its carrying value, the second step of the goodwill impairment test was performed to measure the amount of impairment, if any. In the second step, the fair value of the reporting unit was allocated to the assets and liabilities of the reporting unit as if it had been acquired in a business combination and the purchase price was equivalent to the fair value of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities was referred to as the implied fair value of goodwill. The implied fair value of the reporting unit's goodwill was then compared to the actual carrying value of goodwill. If the implied fair value of goodwill was less than the carrying value of goodwill, an impairment loss is recognized for the difference. ASU 2017-04 removes Step 2 of the goodwill impairment test.

The Company determined the fair value of the reporting unit using a discounted cash flow analysis derived from the Company’s long-term plans. The fair value of the reporting unit was corroborated using market prices for TransEnterix, Inc. The inputs used to determine the fair values were classified as Level 3 in the fair value hierarchy. Based on the impairment test, the Company recorded goodwill impairment of $61.8 million during the second quarter of 2016.

The Company performed a qualitative assessment during the annual impairment review for fiscal 2016 as of December 31, 2016 and concluded that it is not more likely than not that the fair value of the Company’s single reporting unit is less than its carrying amount. Therefore, the two-step goodwill impairment test for the reporting unit was not necessary at December 31, 2016.

9. Goodwill, In-Process Research and Development and Intellectual Property (Continued)

In-Process Research and Development

As described in Note 3, on September 21, 2015, the Company acquired all of the assets related to the Senhance System and recorded $17.1 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 45% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the three months ended March 31, 2017 is as follows:

	In-Process Research and Development
	(In thousands)
Balance at December 31, 2016	$	15,920
Foreign currency translation impact		241
Balance at March 31, 2017		16,161

Intellectual Property

As described in Note 3, on September 21, 2015, the Company acquired all of the developed technology related to the Senhance System and recorded $48.5 million of intellectual property. The estimated fair value of the intellectual property was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 45% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The components of gross intellectual property, accumulated amortization, and net intellectual property as of March 31, 2017 and December 31, 2016 are as follows:

	March 31, 2017										December 31, 2016
	(In thousands)										(In thousands)
	Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Net Carrying Amount
Developed technology	$	48,500	$	(10,092	)	$	(2,393	)	$	36,015	$	48,500	$	(8,458	)	$	(2,952	)	$	37,090

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes Income taxes have been accounted for using the liability method in accordance with ASC 740 “Income Taxes”. The Company computes its interim provision for income taxes by applying the estimated annual effective tax rate method. The Company estimates an annual effective tax rate of 6.2% for the year ending December 31, 2017. This rate does not include the impact of any discrete items. The Company incurred losses for the three month periods ended March 31, 2017 and is forecasting additional losses through the year, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2017. Due to the Company’s history of losses, there is not sufficient evidence to record a net deferred tax asset associated with the U.S., Luxembourg, and Swiss operations. Accordingly, a full valuation allowance has been recorded related to the net deferred tax asset in that jurisdiction. Deferred tax assets and liabilities related to the TransEnterix Italia subsidiary have been recorded as a component of purchase accounting as of the acquisition date. The deferred tax benefit during the three months ended March 31, 2017 and 2016, was approximately $0.9 million and $2.6 million, respectively. There is no net deferred tax asset recorded in relation to TransEnterix Italia and accordingly no valuation allowance has been recorded in that jurisdiction. 10. Income Taxes (Continued) The Company’s effective tax rate for each of the three month periods ended March 31, 2017 and 2016 was 5.3% and 17.0%, respectively. At March 31, 2017, the Company had no unrecognized tax benefits that would affect the Company’s effective tax rate.

Accrued Expenses

3 Months Ended

Mar. 31, 2017

Accrued Liabilities Current [Abstract]

Accrued Expenses

11. Accrued Expenses

The following table presents the components of accrued expenses:

	March 31,		December 31,
	2017		2016
	(In thousands)
Taxes and other assessments	$	2,225	$	2,676
Compensation and benefits		2,291		2,328
Interest and final payment fee		1,100		1,000
Deferred rent		353		323
Consulting and other vendors		593		1,428
Legal and professional fees		142		243
Royalties		162		159
Other		396		49
Total	$	7,262	$	8,206

Notes Payable	3 Months Ended
Notes Payable	Mar. 31, 2017
Debt Disclosure [Abstract]
Notes Payable	12. Notes Payable On January 17, 2012, TransEnterix Surgical entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance LLC (the “Lenders”), which loan and security agreement, as subsequently amended and restated is referred to as the “SVB Loan Agreement.” In connection with the Merger, the Company assumed and became the borrower under the SVB Loan Agreement. On August 14, 2015, the Company entered into the First Amendment to the SVB Loan Agreement (the “First Amendment”) with the Lenders. The first tranche of the First Amendment increased the Company’s borrowings at August 14, 2015 from $10,000,000 to $20,000,000. The First Amendment allowed for interest-only payments at 7.5% per annum through April 30, 2016 and had a maturity date of October 1, 2018. On September 18, 2015, in connection with entry into the Purchase Agreement with Sofar S.p.A. (see Note 3 for a description of the related transactions), the Company and the Lenders entered into the Consent and Second Amendment (the “Second Amendment”) to the SVB Loan Agreement. The Second Amendment modified the period in which the Company could make interest-only payments at 7.5% per annum on the term loans until January 31, 2016. The Second Amendment has a maturity date of July 1, 2018. In connection with the entry into the SVB Loan Agreement and its amendments, the Company became obligated to pay final payment and facility fees. To date, the Company has paid $498,920 in final payment obligations and $255,000 in facility fees under the SVB Loan Agreement. The final payment fee obligation payable under the Second Amendment is 6.5% of the original principal amount of each term loan without the interest only extension and 8.0% with both interest-only extensions. In addition, in connection with the borrowings, the Company issued warrants to the Lenders to purchase shares of the Company’s common stock amounting to an aggregate of 430,815 warrants under the SVB Loan Agreement. Additional warrants will be issued if additional tranche term loans are made. The warrants expire seven years from their respective issue date. The SVB Loan Agreement is secured by a security interest in all assets of the Company and its current and future U.S. subsidiaries, including a security interest in intellectual property proceeds, but excluding a current security interest in intellectual property. The SVB Loan Agreement contains customary representations (tested on a continual basis) and covenants that, subject to exceptions, restrict the Company’s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are not related to its existing business. 12. Notes Payable (Continued) Further, under the Second Amendment, the Lenders consented to the formation of TransEnterix International, the entry of the Company into the Purchase Agreement and other transaction documents, and the name change of TransEnterix Italia. The Company agreed to pledge 100% of the common stock of TransEnterix International as additional security for the borrowings under the SVB Loan Agreement. The Second Amendment added a provision permitting the Company to transfer designated amounts to TransEnterix Italia during the term of the SVB Loan Agreement. This provision for the transfer of designated amount was amended on November 13, 2015 with the Third Amendment to the SVB Loan Agreement. On April 19, 2016, the Company and its U.S. subsidiaries entered into the Consent and Fourth Amendment to the SVB Loan Agreement (the “Fourth Amendment”) pursuant to which TransEnterix International, joined the SVB Loan Agreement and the existing promissory notes as a co-borrower thereunder and pledged, as collateral for the obligations under the SVB Loan Agreement, substantially all of its non-intellectual property assets, including up to 65% of the equity interests owned by TransEnterix International in TransEnterix Europe S.Á.R.L, a wholly owned subsidiary of TransEnterix International. On September 7, 2016, the Company and its U.S. subsidiaries entered into the Fifth Amendment to the SVB Loan Agreement (the “Fifth Amendment”). The Fifth Amendment provides more flexibility to the Company with respect to its intercompany activities with its foreign subsidiaries and adds an affirmative covenant requiring the Company to maintain a $10.0 million cash balance in accounts held with the Lender. Cash amounts related to this requirement are included in restricted cash on the consolidated balance sheet. The Company is in compliance with all covenants as of March 31, 2017 and December 31, 2016. In accordance with ASC 470-50 Debt – Modifications and Extinguishments, it was determined that the debt refinancing on September 26, 2014, was considered to be a debt modification. Accordingly, the Company recorded approximately $129,000 of debt discount, consisting of the $75,000 facility fee and the relative fair value of warrants on the issue date of $54,000. Additionally, approximately $30,000 of legal fees were recorded as a result of the transaction. The debt discount and deferred financing costs will be amortized over the life of the new debt agreement using the effective interest method into interest expense, net. In accordance with ASC 470-50 Debt – Modifications and Extinguishments, it was determined that the debt refinancings on August 14, 2015, September 18, 2015, April 19, 2016 and September 7, 2016 were considered to be debt modifications. Additionally, during the third quarter of 2015, the Company adopted ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. ASU 2015-03 requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The Company recorded a debt discount of approximately $210,000 for these amendments. Accordingly, the unamortized debt discount is presented as a reduction of the related debt liability in the Company’s balance sheet. In accordance with ASU 2015-03, this adopted guidance was applied retrospectively. The debt discount will be amortized over the life of the new debt agreement using the effective interest method into interest expense, net. In connection with the issuance of the notes payable and its amendments, TransEnterix Surgical incurred approximately $371,000 in debt issuance costs paid to lenders and third parties and $280,000 in debt issuance costs related to issuance of warrants to the lenders. The unamortized balance of $76,000 and $107,000 as of March 31, 2017 and December 31, 2016, respectively, will be amortized using the effective interest method.

Restructuring	3 Months Ended
Restructuring	Mar. 31, 2017
Restructuring And Related Activities [Abstract]
Restructuring	13. Restructuring On April 19, 2016, the FDA notified the Company that the SurgiBot System did not meet the criteria for substantial equivalence based on the data submitted in the 510(k) submission. In May 2016, the Company implemented a restructuring plan. Under the restructuring plan, the Company reduced headcount, discontinued efforts on the SurgiBot System, and cancelled certain contracts. The restructuring charges amounted to $5.7 million, of which $2.6 million was included as inventory write down related to restructuring and $3.1 million was included as restructuring and other charges in the consolidated statements of operations and comprehensive loss, during the second quarter of 2016. The restructuring and other charges of $3.1 million included: (i) $0.5 million to be paid in cash, of which $0.4 million related to employee severance costs and $0.1 million related to cancellation of certain contracts; and (ii) $2.6 million for other non-cash charges, of which $1.0 million related to the disposal of long-lived assets for the abandonment of certain equipment and tooling directly relating to the SurgiBot System and $1.6 million related to the write-off of intellectual property for certain patents also relating to the SurgiBot System.

Equity Line Financing, Controlled Equity Offering and Public Offering of Common Stock

3 Months Ended

Mar. 31, 2017

Text Block [Abstract]

Equity Line Financing, Controlled Equity Offering and Public Offering of Common Stock

14. Equity Line Financing, Controlled Equity Offering and Public Offering of Common Stock

On December 16, 2016, the Company entered into a purchase agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC, (“Lincoln Park”), pursuant to which the Company has the right to sell to Lincoln Park up to an aggregate of $25.0 million in shares of the Company’s common stock, (the “Common Stock”), subject to certain limitations and conditions set forth in the LPC Purchase Agreement. From time to time on any trading day the Company selects, the Company has the right, in its sole discretion, subject to the conditions and limitations in the LPC Purchase Agreement, to direct Lincoln Park to purchase up to 150,000 shares of Common Stock (each such purchase, a “Regular Purchase”) over the 36-month term of the LPC Purchase Agreement. The purchase price of shares of Common Stock pursuant to the LPC Purchase Agreement will be based on the prevailing market price at the time of sale as set forth in the LPC Purchase Agreement. There are no trading volume requirements or restrictions under the Purchase Agreement. Lincoln Park’s obligation under each Regular Purchase shall not exceed $2.0 million. There is no upper limit on the price per share that Lincoln Park must pay for Common Stock under the LPC Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the Company’s closing price is less than the floor price as set forth in the LPC Purchase Agreement. Both the amount and frequency of the Regular Purchases can be increased upon the mutual agreement of the Company and Lincoln Park. The Company will control the timing and amount of any sales of shares of Common Stock to Lincoln Park. The Company may, in its sole discretion, direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a Regular Purchase the closing sale price of the Common Stock is not below the threshold price as set forth in the LPC Purchase Agreement. The Company and Lincoln Park may mutually agree to increase the amount of Common Stock sold to Lincoln Park on any accelerated purchase date. The Company issued to Lincoln Park 345,421 shares of Common Stock as commitment shares in consideration for the LPC Purchase Agreement through March 31, 2017. The Company shall issue pro rata up to an additional 119,551 shares of Common Stock to Lincoln Park as determined by the number of shares Common Stock purchased by Lincoln Park pursuant to the LPC Purchase Agreement. All sales of shares have been and will continue to be made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. Sales under the LPC Purchase Agreement for the year ended December 31, 2016 were 300,000 shares, with gross proceeds of $412,500 and net proceeds of $392,500. Sales under the LPC Purchase Agreement for the three months ended March 31, 2017 were 3,972,741 shares, with gross and net proceeds of $5,304,000.

Effective April 27, 2017, the Company terminated the LPC Purchase Agreement. The LPC Purchase Agreement provided the Company with an election to terminate the Purchase Agreement for any reason or for no reason by delivering a notice to Lincoln Park, and the Company did not incur any early termination penalties in connection with the termination of the LPC Purchase Agreement. Prior to termination, the Company sold shares of its Common Stock to Lincoln Park under the LPC Purchase Agreement for gross proceeds of approximately $5.7 million.

On February 20, 2015, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “2015 Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which the Company sold through Cantor, from time to time, up to $25.0 million in shares of common stock in an at-the-market offering. All sales of shares were made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The Company pays Cantor a commission of approximately 3% of the aggregate gross proceeds received from all sales of common stock under the Sales Agreement. Sales under the 2015 Sales Agreement have been fully sold as of February 9, 2016, with cumulative shares of 7,724,488, gross proceeds of $25.0 million and net proceeds of $24.0 million.

On February 9, 2016, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the “2016 Sales Agreement”) with Cantor, as sales agent, pursuant to which the Company can sell through Cantor, from time to time, up to $43.6 million in shares of common stock in an at-the-market offering. All sales of shares have been and will continue to be made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The Company pays Cantor a commission of approximately 3% of the aggregate gross proceeds received from all sales of common stock under the 2016 Sales Agreement. Unless otherwise terminated earlier, the 2016 Sales Agreement continues until all shares available under the Sales Agreement have been sold. There we no sales under the Sales Agreements for the three months ended March 31, 2017.

14. Equity Line Financing, Controlled Equity Offering and Public Offering of Common Stock (Continued)

The following table summarizes the total sales under the 2015 Sales Agreement and 2016 Sales Agreement for the periods indicated (in thousands, except per share amounts):

	2016 Sales Agreement		2015 Sales Agreement
	Year Ended December 31, 2016		Year Ended December 31, 2016		Year Ended December 31, 2015
Total shares of common stock sold		8,763.4		5,710.2		2,014.3
Average price per share	$	4.70	$	3.23	$	3.25
Gross proceeds	$	41,156	$	18,454	$	6,546
Commissions earned by Cantor	$	1,235	$	553	$	197
Other issuance costs	$	185	$	—	$	259

As of March 31, 2017, the Company had two effective shelf registration statements on file with the SEC, each of which were initially filed to register up to $100.0 million of debt securities, common stock, preferred stock, or warrants, or any combination thereof for future financing transactions, one filed in January 2014 and the other filed in November 2014. In March 2016, the November 2014 shelf registration statement was increased by $50.0 million. From April 2014 through December 2016, we have raised $179.2 million in gross proceeds and approximately $168.8 million in net proceeds under such shelf registration statements through public offerings of our securities. As of March 31, 2017, we had $37.8 million available for future financings under such shelf registration statements. In addition, approximately $2.4 million was reserved for future issuances under the 2016 ATM Offering under the January 2014 shelf registration statement, which expired in April 2017, and $19.5 million was reserved for future issuances under the LPC Purchase Agreement, which was terminated in April 2017 (see above in this Note 14).

See Note 18 (Subsequent Events) for a description of an offering made under the November 2014 shelf registration statement in April 2017.

Basic and Diluted Net Loss per Share	3 Months Ended
Basic and Diluted Net Loss per Share	Mar. 31, 2017
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	15. Basic and Diluted Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and restricted stock units. In computing diluted net loss per share for the three months ended March 31, 2017 and 2016, no adjustment has been made to the weighted average outstanding common shares as the assumed exercise of outstanding options and warrants and restricted stock units would be anti-dilutive.

Related Person Transactions	3 Months Ended
Related Person Transactions	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Person Transactions	16. Related Person Transactions On September 18, 2015, TransEnterix Italia entered into a services agreement for receipt of administrative services from Sofar and payment of rent to Sofar, a stockholder that owned approximately 16% and 14% of the Company’s common stock at March 31, 2017 and 2016, respectively. Expenses under this agreement were approximately $52,000 and $80,000 for the three months ended March 31, 2017 and 2016, respectively. In November 2016, the Company agreed to enter into a technology and patents purchase agreement with Sofar to acquire from Sofar certain technology and intellectual property rights related to the Senhance Acquisition, and formerly licensed by the Company. The acquisition price was €375,000. As discussed in Note 3, in September 2015, the Company completed the Senhance Acquisition using a combination of cash, stock and potential post-acquisition milestone payments. On December 30, 2016, the Company entered into an Amendment to the Senhance Acquisition purchase agreement with Sofar to restructure the terms of the Second Tranche of the Cash Consideration. Under the Amendment, the Second Tranche was restructured to reduce the contingent cash consideration by €5.0 million in exchange for the issuance of 3,722,685 shares of the Company’s common stock with an aggregate fair market value of €5.0 million. On January 4, 2017, the Company issued to Sofar 3,722,685 shares of the common stock with a fair value of €5.0 million. The price per share was $1.404 and was calculated based on the average of the closing prices of the Company’s common stock on ten consecutive trading days ending one day before the execution of the Amendment.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	17. Commitments and Contingencies Contingent Consideration As discussed in Note 3, in September 2015, the Company completed the Senhance Acquisition using a combination of cash, stock and potential post-acquisition milestone payments. These milestone payments may be payable in the future, depending on the achievement of certain regulatory and commercial milestones. On December 30, 2016, the Company entered into an Amendment to restructure the terms of the Second Tranche of the Cash Consideration. Under the Amendment, the Second Tranche was restructured to reduce the contingent cash consideration by €5.0 million in exchange for the issuance of 3,722,685 shares of the Company’s common stock with an aggregate fair market value of €5.0 million. As of December 31, 2016, the fair value of the contingent consideration was $22.8 million. On March 31, 2017, after the issuance of 3,722,685 shares of the Company’s common stock, the fair value of the contingent consideration was $18.8 million. Legal Proceedings When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimating an amount or range of possible losses resulting from litigation proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, are in the early stages of the proceedings, and are subject to appeal. In addition, because most legal proceedings are resolved over extended periods of time, potential losses are subject to change due to, among other things, new developments, changes in legal strategy, the outcome of intermediate procedural and substantive rulings and other parties’ settlement posture and their evaluation of the strength or weakness of their case against the Company. For these reasons, the Company is currently unable to predict the ultimate timing or outcome of, or reasonably estimate the possible losses or a range of possible losses resulting from, the matters described above. Based on information currently available, the Company does not believe that any reasonably possible losses arising from currently pending legal matters will be material to the Company’s results of operations or financial condition. However, in light of the inherent uncertainties involved in such matters, an adverse outcome in one or more of these matters could materially and adversely affect the Company’s financial condition, results of operations or cash flows in any particular reporting period. No liability or related charge was recorded to earnings in the Company’s consolidated financial statements for legal contingencies for the three months ended March 31, 2017 or the year ended December 31, 2016. On June 2, 2016 a stockholder filed a putative class action complaint, Ashok V. Bankley, individually and on behalf of all others similarly situated vs. TransEnterix, Inc., Todd M. Pope and Joseph P. Slattery , in the United States District Court for the Eastern District of North Carolina (Case No. 5:16-cv-00313-D) (the “Initial Complaint”), against the Company and two of its executive officers on behalf of all persons who purchased or otherwise acquired the Company’s common stock between February 10, 2016 and May 10, 2016. On August 4, 2016, the defendants filed a motion to dismiss the Initial Complaint for failure to state a claim under the securities laws. On August 30, 2016, the court appointed Randall Clark, Samir Patel, the Underhill Cemetery Association, and the North Underhill Cemetery Association as the lead plaintiffs in the Initial Complaint, and also provided the plaintiffs an opportunity to amend the Initial Complaint. On September 26, 2016, the lead plaintiffs filed an Amended Complaint. Among other things, the Amended Complaint asserts revised claims against the Company and Messrs. Pope and Slattery, and adds claims against certain current and former members of the Company’s Board of Directors, and Cantor Fitzgerald & Co., the sales agent under the 2016 Sales Agreement, under which the Company offered and sold, through Cantor, shares of common stock in its 2016 ATM Offering. The Amended Complaint alleges that the defendants made false and misleading public statements related to the Company's SurgiBot System and its 510(k) application in violation of certain federal securities laws. The Amended Complaint seeks class certification of a class consisting of all persons who purchased or otherwise acquired the Company’s common stock between February 10, 2016 and May 10, 2016, class certification of a subclass of persons who purchased or otherwise acquired the Company’s common stock in connection with the 2016 ATM Offering between February 9, 2016 and April 19, 2016, unspecified monetary damages, costs, and attorneys’ fees. On November 8, 2016, the defendants moved to dismiss the Amended Complaint, which the plaintiffs later opposed. As of January 23, 2017, the motions to dismiss were fully briefed and deemed submitted to the court for decision. On June 9, 2016, a different stockholder filed another putative class action complaint, captioned Thomas Ravey, individually and on behalf of all others similarly situated vs. TransEnterix, Inc., Todd M. Pope and Joseph P. Slattery, in the United States District Court for the Middle District of North Carolina (Case No. 1:16-cv-599) (the “Ravey Action”). The Ravey Action asserted substantially similar claims against the same defendants and sought substantially similar relief as the Initial Complaint. On August 4, 2016, the plaintiff in the Ravey Action voluntarily dismissed the Ravey Action. 17. Commitments and Contingencies (Continued) On July 8, 2016, a stockholder filed a different putative derivative complaint, captioned Otto Pikal v. Todd M. Pope, et al., in the General Court of Justice, Superior Court Division, Wake County, North Carolina (case number 16CV008930) (the “Pikal Action”), on behalf of the Company against certain of our current officers and directors. The complaint alleges, among other things, that the defendants breached their fiduciary duties by disseminating false and misleading information to the Company’s shareholders relating to the Company’s SurgiBot System and its 510(k) application in violation of certain federal securities laws and by failing to ensure that the Company maintained adequate internal controls. The complaint seeks, among other things, unspecified monetary damages and an order directing the Company to take steps to improve its corporate governance and to protect the Company and its stockholders from future wrongdoing such as that alleged in the complaint. On September 29, 2016, the court entered an order staying the Pikal Action pending resolution of the motion to dismiss the Amended Complaint in the Bankley Action. On March 3, 2017, a different stockholder filed another putative class action complaint on behalf of the Company, captioned Scott Maine vs. Paul LaViolette, et al., in the Court of Justice, Superior Court Division, Wake County, North Carolina (case number 17CV002590) (the “Maine Action”). The complaint in the Maine Action is substantially similar to the complaint in the Pikal Action, asserting similar claims and seeking similar relief against largely the same group of defendants named in the complaint in the Pikal Action. On April 11, 2017, the court entered an order staying the Maine Action pending resolution of the motion to dismiss the Amended Complaint in the Bankley Action. On April 25, 2016, Intuitive Surgical, Inc. and its French subsidiary, Intuitive Surgical SAS (collectively, “Intuitive”), brought a request for unilateral measures of enquiry in front of the President of the Commercial Court of Toulon (France) (the “President”) against two employees of TransEnterix International, Inc. alleging that the Company, through these two employees, engaged in acts of unfair competition. On May 3, 2016, the President rendered an order granting Intuitive’s request for unilateral measures of enquiry with respect to its allegations (the “Order”). On June 28, 2016, TransEnterix International filed a writ challenging the Order and requesting that it be withdrawn by the President. On September 7, 2016, the President rendered his decision on TransEnterix International’s challenge (the “Ruling”) and ruled in favor of TransEnterix International. Under the Ruling, the Intuitive unilateral measures of enquiry were declared to be unjustified and the Order was withdrawn. The President also declared that the Ruling was provisionally enforceable. Intuitive has filed an appeal against the Ruling (the “Appeal”) with the Court of Appeal of Aix-en-Provence (France). Because Intuitive did not comply with the Ruling, TransEnterix International filed a dismissal request against the Appeal with the same Court of Appeal (the “Dismissal Request”). Currently, Intuitive’s counsel advised TransEnterix International’s counsel of their intent to waive the Appeal (the “Waiver”). A hearing regarding the Dismissal Request took place on March 7, 2017 at which hearing the Waiver was formalized. On April 4, 2017, the Court of Appeal declared the litigation terminated. As a result, the Dismissal Request, as well as the Appeal, was struck off the agenda of the Court of Appeal making the Ruling (dated September 7, 2016) in favor of TransEnterix International final.

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Public Offering On April 28, 2017, the Company sold 24.9 million units, each consisting of one share of the Company’s common stock, a Series A warrant to purchase one share of common stock, and a Series B warrant to purchase 0.75 shares of common stock, at a public offering price of $1.00 per unit for aggregate gross proceeds of $24.9 million in an underwritten firm commitment public offering. Net proceeds after issuance costs were $23.2 million, assuming no exercise of the warrants. The closing of the public offering occurred on May 3, 2017. The offering was made under the November 2014 shelf registration statements and a related registration statement filed under Rule 462(b) promulgated under the Securities Act of 1933, as amended. As of May 3, 2017, the November 2014 shelf registration statement was fully utilized. Termination of Lincoln Park Purchase Agreement As discussed in Note 14, effective April 27, 2017, the Company terminated the LPC Purchase Agreement. The LPC Purchase Agreement provided the Company with an election to terminate the LPC Purchase Agreement for any reason or for no reason by delivering a notice to Lincoln Park, and the Company did not incur any early termination penalties in connection with the termination of the LPC Purchase Agreement. Prior to termination, the Company sold shares of its Common Stock to Lincoln Park under the LPC Purchase Agreement for gross proceeds of approximately $5.7 million. 18. Subsequent Events (continued) Debt Refinancing On May 10, 2017, the Company and its domestic subsidiaries, as co-borrowers, entered into a Loan and Security Agreement (the “Innovatus Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP, as Lender and Collateral Agent (the “Lender”). Under the Innovatus Loan Agreement, the Lender has agreed to make certain term loans in the aggregate principal amount of up to $17,000,000. Funding of the first $14,000,000 tranche is expected to occur upon the satisfaction of customary funding conditions. The Company will be eligible to draw on the second tranche of $3,000,000 upon achievement of certain milestones, including Senhance Clearance (as defined below). So long as the Company meets each Interest-Only Milestone (as defined below), the Company is entitled to make interest-only payments for up to twenty-four (24) months. At the end of the interest-only period, the Company will be required to repay the term loans over a two-year period, based on a twenty-four (24) month amortization schedule, with a final maturity date occurring on the fourth anniversary of the initial funding date. However, the interest-only period will end if the Company fails to meet any Interest-Only Milestone. Commencing on the first day of the month following such failure to achieve an Interest-Only Milestone, the Company will be required to repay the term loans over a two year period, based on a twenty-four (24) month amortization schedule. The Interest-Only Milestones require the Company to (i) achieve certain twelve month revenue targets, measured quarterly, commencing with quarter ending March 31, 2018, (ii) meet a minimum capital raising threshold through the sale and issuance of equity securities during the period from April 10, 2017 through May 31, 2018 and (iii) obtain clearance for commercialization of the Senhance System by the U.S. Food and Drug Administration (“Senhance Clearance”) by May 30, 2018 (each such milestone, an “Interest-Only Milestone”). In connection with its entrance into the Innovatus Loan Agreement, the Company repaid its existing credit facility with Silicon Valley Bank and Oxford Finance LLC under the SVB Loan Agreement. The term loans bear interest at a fixed rate equal to 11% per annum, of which 2.5% can be paid in-kind and added to the outstanding principal amount of the term loans until the earlier of (i) the first anniversary following the funding date and (ii) the Company’s failure to achieve an Interest-Only Milestone. The Company will be required to repay the term loans if they are accelerated following an event of default. In addition, the Company is permitted to prepay the term loans in full at any time upon five (5) business days’ written notice to the Lenders. Upon the earliest to occur of the maturity date, acceleration of the term loan, or prepayment of the term loan, the Company is required to make a final payment equal to the total term loan commitment multiplied by four percent (4%) (the “Final Fee”); provided, however, that in the event the Company refinances its obligations with the Lender after Senhance Clearance, no Final Fee or Prepayment Fee (as defined below) will be due thereunder ; and provided, further, that if the Company elects to refinance its obligations prior to the funding of the second tranche, the Final Fee with respect to the second tranche shall be paid in full on the date of such refinancing. Any prepayment of the term loans in full, whether mandatory or voluntary, must include (i) the Final Fee, (ii) interest at the default rate (which is the rate otherwise applicable plus five percent (5%)) with respect to any amounts past due, (iii) the Lenders’ expenses and all other obligations that are due and payable to the Lenders and (iv) a prepayment fee of three percent (3%) if the term loan is paid in full on or before the first anniversary of the effective date, two percent (2%) if paid off after the first anniversary but on or before the second anniversary of the effective date and one percent (1%) if paid off after the second anniversary but on or before the third anniversary of the effective date (the “Prepayment Fee”). In connection with the funding, the Company is obligated to make a facility fee payment of $170,000 on the date of funding of the first tranche. In addition, the Company will issue warrants to the Lender to purchase shares of the Company’s common stock. The warrants will be issued on the funding date of each tranche and will expire five (5) years from such issue date. The warrant to be issued in connection with funding of the first tranche will entitle the Lender to purchase up to 1,244,746 shares of the Company’s common stock at an exercise price of $1.00 per share. The Company’s obligations under the Innovatus Loan Agreement are secured by a security interest in all of the assets of the Company and its current and future domestic and material foreign subsidiaries, including a security interest in the intellectual property. The Innovatus Loan Agreement contains customary representations and covenants that, subject to exceptions, restrict the Company’s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are not related to its existing business. Under the terms of the Innovatus Loan Agreement, the Company is required to maintain minimum unrestricted cash in an amount equal to (x) six million dollars ($6,000,000), at all times prior to Senhance Clearance; and (y) at all times thereafter, the least of (i) $6,000,000, (ii) the Company’s trailing three (3) months’ cash used to fund operating activities, as determined as of the most recent month end and (iii) the then outstanding principal amount of the term loans, together with accrued but unpaid interest. .

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

Going Concern

Use of Estimates

Cash and Cash Equivalents and Restricted Cash

Fair Value of Financial Instruments

Concentrations and Credit Risk

Accounts Receivable

Inventories

Identifiable Intangible Assets and Goodwill

In-Process Research and Development

Property and Equipment

Property and equipment consists primarily of machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost.

Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

Machinery, manufacturing and demonstration equipment		3-5 years
Computer equipment		3 years
Furniture		5 years
Leasehold improvements		Lesser of lease term or 3 to 10 years

Impairment of Long-Lived Assets

Contingent Consideration

Translation of Foreign Currencies

Risk and Uncertainties

Revenue Recognition

•

Instruments and accessories. Revenue from sales of instruments and accessories is generally recognized at the time of shipment.

•

Service. Service revenue is recognized ratably over the term of the service period. Revenue related to services performed on a time-and-materials basis is recognized when it is earned and billable.

2. Summary of Significant Accounting Policies (Continued)

Research and Development Costs

Stock-Based Compensation

Income Taxes

Segments

Impact of Recently Issued Accounting Standards

2. Summary of Significant Accounting Policies (Continued)

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Estimated Lives of Assets

Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

Machinery, manufacturing and demonstration equipment		3-5 years
Computer equipment		3 years
Furniture		5 years
Leasehold improvements		Lesser of lease term or 3 to 10 years

Fair Value (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Summary of Assets Measured at Fair Value on Recurring Basis

	March 31, 2017
	(In thousands)
	(unaudited)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	13,086	$	—	$	—	$	13,086
Restricted cash		10,432		—		—		10,432
Total Assets measured at fair value	$	23,518	$	—	$	—	$	23,518
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	18,800	$	18,800
Total liabilities measured at fair value	$	—	$	—	$	18,800	$	18,800

	December 31, 2016
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets measured at fair value
Cash and cash equivalents	$	24,165	$	—	$	—	$	24,165
Restricted cash		10,425		—		—		10,425
Total Assets measured at fair value	$	34,590	$	—	$	—	$	34,590
Liabilities measured at fair value
Contingent consideration	$	—	$	—	$	22,800	$	22,800
Total liabilities measured at fair value	$	—	$	—	$	22,800	$	22,800

Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3

Valuation

Methodology

Significant

Unobservable Input

Weighted Average

(range, if

applicable)

Contingent consideration

Probability weighted

income approach

Milestone dates

2016 to 2017

Discount rate

Probability of occurrence

7.5% to 9.0%

100%

Change in Fair Value for All Assets and Liabilities Using Unobservable Level 3 Inputs As Determined By Level 3 Inputs

The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs for the three months ended March 31, 2017:

	Fair Value Measurement at Reporting Date (Level 3)
	(In thousands)
	(unaudited)
Balance at December 31, 2016	$	22,800
Conversion of contingent consideration to common stock		(5,227	)
Change in fair value		1,227
Balance at March 31, 2017	$	18,800
Current portion		6,250
Long-term portion		12,550
Balance at March 31, 2017	$	18,800

Accounts Receivable, Net (Tables)

3 Months Ended

Mar. 31, 2017

Receivables [Abstract]

Summary of Accounts Receivable

The following table presents the components of accounts receivable:

	March 31,			December 31,
	2017			2016
	(In thousands)
Gross accounts receivable	$	1,901		$	960
Allowance for uncollectible accounts		(73	)		(73	)
Total accounts receivable, net	$	1,828		$	887
Short-term portion	$	1,828		$	621
Long-term portion		—			266
Total accounts receivable	$	1,828		$	887

Inventories (Tables)

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory

The components of inventories are as follows:

	March 31,		December 31,
	2017		2016
	(In thousands)
Finished goods	$	3,359	$	4,698
Raw materials		4,962		3,185
Total inventories	$	8,321	$	7,883

Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

The following table presents the components of other current assets:

	March 31,		December 31,
	2017		2016
	(In thousands)
Prepaid expenses	$	1,118	$	2,186
Advances to vendors		3,967		1,806
Other receivables		516		1,343
Total	$	5,601	$	5,335

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2017

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following:

	March 31,			December 31,
	2017			2016
	(In thousands)
Machinery, manufacturing and demonstration equipment	$	8,088		$	7,579
Computer equipment		2,134			2,124
Furniture		624			614
Leasehold improvements		2,067			2,028
Total property and equipment		12,913			12,345
Accumulated depreciation and amortization		(7,113	)		(6,573	)
Property and equipment, net	$	5,800		$	5,772

Goodwill, In-Process Research and Development and Intellectual Property (Tables)

3 Months Ended

Mar. 31, 2017

Carrying Value of Goodwill and Change in Balance

The carrying value of goodwill and the change in the balance for the three months ended March 31, 2017 is as follows:

	Goodwill
	(In thousands)
Balance at December 31, 2016	$	68,697
Foreign currency translation impact		287
Balance at March 31, 2017	$	68,984

Carrying Value of Company's Intangible Assets and Change in Balance

The components of gross intellectual property, accumulated amortization, and net intellectual property as of March 31, 2017 and December 31, 2016 are as follows:

	March 31, 2017										December 31, 2016
	(In thousands)										(In thousands)
	Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Foreign currency translation impact			Net Carrying Amount
Developed technology	$	48,500	$	(10,092	)	$	(2,393	)	$	36,015	$	48,500	$	(8,458	)	$	(2,952	)	$	37,090

In-Process Research and Development [Member]

Carrying Value of Company's Intangible Assets and Change in Balance

The carrying value of the Company’s IPR&D assets and the change in the balance for the three months ended March 31, 2017 is as follows:

	In-Process Research and Development
	(In thousands)
Balance at December 31, 2016	$	15,920
Foreign currency translation impact		241
Balance at March 31, 2017		16,161

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2017

Accrued Liabilities Current [Abstract]

Schedule of Accrued Expenses

The following table presents the components of accrued expenses:

	March 31,		December 31,
	2017		2016
	(In thousands)
Taxes and other assessments	$	2,225	$	2,676
Compensation and benefits		2,291		2,328
Interest and final payment fee		1,100		1,000
Deferred rent		353		323
Consulting and other vendors		593		1,428
Legal and professional fees		142		243
Royalties		162		159
Other		396		49
Total	$	7,262	$	8,206

Equity Line Financing, Controlled Equity Offering and Public Offering of Common Stock (Tables)

3 Months Ended

Mar. 31, 2017

Text Block [Abstract]

Schedule of Total Sales under 2015 and 2016 Sales Agreement

The following table summarizes the total sales under the 2015 Sales Agreement and 2016 Sales Agreement for the periods indicated (in thousands, except per share amounts):

	2016 Sales Agreement		2015 Sales Agreement
	Year Ended December 31, 2016		Year Ended December 31, 2016		Year Ended December 31, 2015
Total shares of common stock sold		8,763.4		5,710.2		2,014.3
Average price per share	$	4.70	$	3.23	$	3.25
Gross proceeds	$	41,156	$	18,454	$	6,546
Commissions earned by Cantor	$	1,235	$	553	$	197
Other issuance costs	$	185	$	—	$	259

Organization and Capitalization - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017 Segment shares	Dec. 31, 2016 shares	Dec. 06, 2013 $ / shares shares
Organization And Capitalization [Line Items]
Common stock, shares authorized	750,000,000	750,000,000
Preferred stock, shares authorized			25,000,000
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.01
Number of business segments \| Segment	1
Minimum [Member]
Organization And Capitalization [Line Items]
Common stock, shares authorized			225,000,000
Maximum [Member]
Organization And Capitalization [Line Items]
Common stock, shares authorized			750,000,000

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) Segment	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Accounting Policies [Line Items]
Accumulated deficit	$ (318,258,000)		$ (302,844,000)
Restricted cash	10,432,000		10,425,000
Impairment charges	$ 0		0
Period of free service sale arrangement	1 year
Number of business segments \| Segment	1
Goodwill	$ 166,352,000		$ 176,249,000
U.S. [Member]
Accounting Policies [Line Items]
Percentage of total consolidated assets	44.00%
International [Member]
Accounting Policies [Line Items]
Percentage of total consolidated assets, excluding goodwill	44.00%		40.00%
Senhance Surgical Robotic System Acquisition [Member] \| Europe [Member]
Accounting Policies [Line Items]
Goodwill	$ 92,600,000
Stock Options [Member]
Accounting Policies [Line Items]
Share based compensation, expense recognized	$ 2,139,000	$ 1,428,000
Minimum [Member]
Accounting Policies [Line Items]
Amortization period	7 years
Maximum [Member]
Accounting Policies [Line Items]
Amortization period	10 years
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Three [Member]
Accounting Policies [Line Items]
Concentration Risk Percentage	100.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Accounting Policies [Line Items]
Concentration Risk Percentage			100.00%
Held In Cash Money Market Account [Member]
Accounting Policies [Line Items]
Restricted cash	$ 10,000,000
Held In Cash Collateral Accounts [Member]
Accounting Policies [Line Items]
Restricted cash	$ 432,000

Summary of Significant Accounting Policies - Summary of Estimated Lives of Assets (Detail)	3 Months Ended
	Mar. 31, 2017
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	Lesser of lease term or 3 to 10 years
Minimum [Member] \| Machinery, Manufacturing and Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Minimum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Maximum [Member] \| Machinery, Manufacturing and Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Maximum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Acquisition of Senhance Surgical Robotic System - Additional Information (Detail)				3 Months Ended	12 Months Ended
	Mar. 21, 2017	Dec. 30, 2016 EUR (€) shares	Sep. 21, 2015 USD ($) shares	Mar. 31, 2017 EUR (€)	Dec. 31, 2016 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 30, 2016 USD ($)	Dec. 30, 2016 EUR (€)	Sep. 21, 2015 EUR (€)
Business Acquisition [Line Items]
Securities consideration held in escrow percentage			10.00%
Escrow and security interest period			24 months
Senhance Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Common shares issued \| shares			15,543,413
Percentage of securities consideration released from lock out restrictions	75.00%
Acquisition agreement, description				With respect to the remaining twenty-five percent of the Securities Consideration, it remains locked-up until the two-year anniversary of the Closing Date.
Senhance Surgical Robotic System Acquisition [Member] \| Ending on Two Year Anniversary [Member]
Business Acquisition [Line Items]
Percentage of securities consideration	25.00%
Senhance Surgical Robotic System Acquisition [Member] \| First Tranche [Member]
Business Acquisition [Line Items]
Cash consideration \| $			$ 25,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member]
Business Acquisition [Line Items]
Common shares issued \| shares		3,722,685
Cash consideration payable								€ 10,000,000
Aggregate fair market value		€ 5,000,000
Aggregate fair market value payment								€ 5,000,000
Gross proceeds from financing \| $							$ 50,000,000
Interest rate							9.00%	9.00%
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member] \| Lincoln Park Capital Fund, LLC [Member]
Business Acquisition [Line Items]
Gross proceeds from financing \| $						$ 50,000,000
Interest rate						9.00%
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Cash on hand \| $							$ 50,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member] \| Minimum [Member] \| Lincoln Park Capital Fund, LLC [Member]
Business Acquisition [Line Items]
Cash on hand \| $						$ 50,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Third Tranche [Member]
Business Acquisition [Line Items]
Cash consideration payable									€ 15,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Third Tranche [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Target revenue to be achieved									25,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Fourth Tranche [Member]
Business Acquisition [Line Items]
Cash consideration				€ 1,100,000	€ 1,100,000
Cash consideration payable									2,500,000
Senhance Surgical Robotic System Acquisition [Member] \| U.S. Dollars [Member]
Business Acquisition [Line Items]
Cash consideration \| $			$ 25,000,000
Senhance Surgical Robotic System Acquisition [Member] \| Euro [Member]
Business Acquisition [Line Items]
Cash consideration payable									€ 27,500,000
TransEnterix Italia [Member]
Business Acquisition [Line Items]
Membership interests percentage under Security agreement									10.00%

Fair Value - Summary of Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Assets measured at fair value
Cash and cash equivalents	$ 13,086	$ 24,165
Restricted cash	10,432	10,425
Total Assets measured at fair value	23,518	34,590
Liabilities measured at fair value
Contingent consideration	18,800	22,800
Total liabilities measured at fair value	18,800	22,800
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets measured at fair value
Cash and cash equivalents	13,086	24,165
Restricted cash	10,432	10,425
Total Assets measured at fair value	23,518	34,590
Significant Unobservable Inputs (Level 3) [Member]
Liabilities measured at fair value
Contingent consideration	18,800	22,800
Total liabilities measured at fair value	$ 18,800	$ 22,800

Fair Value - Additional Information (Detail) - USD ($)	3 Months Ended
Fair Value - Additional Information (Detail) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Senhance Surgical Robotic System Acquisition [Member]
Fair Value Measurements Disclosure [Line Items]
Fair value of contingent consideration	$ 1,227,000	$ 856,000

Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) - Senhance Surgical Robotic System Acquisition [Member] - Significant Unobservable Inputs (Level 3) [Member] - Contingent Consideration [Member]	3 Months Ended
	Mar. 31, 2017
Fair Value Inputs Liabilities Quantitative Information [Line Items]
Probability of occurrence	100.00%
Minimum [Member]
Fair Value Inputs Liabilities Quantitative Information [Line Items]
Milestone dates	2016
Discount rate	7.50%
Maximum [Member]
Fair Value Inputs Liabilities Quantitative Information [Line Items]
Milestone dates	2017
Discount rate	9.00%

Fair Value - Change in Fair Value for All Assets and Liabilities Using Unobservable Level 3 Inputs As Determined By Level 3 Inputs (Detail) - Fair Value Measurement at Reporting Date (Level 3) [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 22,800
Conversion of contingent consideration to common stock	(5,227)
Change in fair value	1,227
Current portion	6,250
Long-term portion	12,550
Ending balance	$ 18,800

Accounts Receivable, Net - Summary of Accounts Receivable (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Receivables [Abstract]
Gross accounts receivable	$ 1,901	$ 960
Allowance for uncollectible accounts	(73)	(73)
Total accounts receivable, net	1,828	887
Short-term portion	$ 1,828	621
Long-term portion		$ 266

Inventories - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 3,359	$ 4,698
Raw materials	4,962	3,185
Total inventories	$ 8,321	$ 7,883

Other Current Assets - Schedule of Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 1,118	$ 2,186
Advances to vendors	3,967	1,806
Other receivables	516	1,343
Total	$ 5,601	$ 5,335

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 12,913	$ 12,345
Accumulated depreciation and amortization	(7,113)	(6,573)
Property and equipment, net	5,800	5,772
Machinery, Manufacturing and Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	8,088	7,579
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	2,134	2,124
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	624	614
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 2,067	$ 2,028

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation	$ 532,000	$ 565,000

Goodwill, In-Process Research and Development and Intellectual Property - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Sep. 21, 2015	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets [Line Items]
Goodwill			$ 68,984	$ 68,697
Goodwill impairment		$ 61,800
In-process research and development			16,161	15,920
In-Process Research and Development [Member]
Goodwill And Intangible Assets [Line Items]
In-process research and development			16,161	$ 15,920
Discount rate	45.00%
Intellectual Property [Member]
Goodwill And Intangible Assets [Line Items]
Discount rate	45.00%
Safe Stitch Medical Inc [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill			93,800
Senhance Surgical Robotic System Acquisition [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill			$ 38,300
Intellectual property	$ 48,500
Senhance Surgical Robotic System Acquisition [Member] \| In-Process Research and Development [Member]
Goodwill And Intangible Assets [Line Items]
In-process research and development	$ 17,100

Goodwill, In-Process Research and Development and Intellectual Property - Carrying Value of Goodwill and Change in Balance (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 68,697
Foreign currency translation impact	287
Ending balance	$ 68,984

Goodwill, In-Process Research and Development and Intellectual Property - Carrying Value of Company's IPR&D Assets and Change in Balance (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Finite-Lived Intangible Assets [Line Items]
Beginning balance	$ 15,920
Ending balance	16,161
In-Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	15,920
Foreign currency translation impact	241
Ending balance	$ 16,161

Goodwill, In-Process Research and Development and Intellectual Property - Summary of Gross Intellectual Property, Accumulated Amortization, and Net Intellectual Property (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Net Carrying Amount	$ 36,015	$ 37,090
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	48,500	48,500
Accumulated Amortization	(10,092)	(8,458)
Foreign currency translation impact	(2,393)	(2,952)
Net Carrying Amount	$ 36,015	$ 37,090

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2017
Income Tax Contingency [Line Items]
Deferred tax benefit	$ 900,000	$ 2,600,000
Effective tax rate	5.30%	17.00%
Unrecognized tax benefits	$ 0
Scenario, Forecast [Member]
Income Tax Contingency [Line Items]
Estimated annual effective tax rate			6.20%

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities Current [Abstract]
Taxes and other assessments	$ 2,225	$ 2,676
Compensation and benefits	2,291	2,328
Interest and final payment fee	1,100	1,000
Deferred rent	353	323
Consulting and other vendors	593	1,428
Legal and professional fees	142	243
Royalties	162	159
Other	396	49
Total	$ 7,262	$ 8,206

Notes Payable - Additional Information (Detail) - USD ($)				3 Months Ended
	Sep. 18, 2015	Aug. 14, 2015	Sep. 26, 2014	Mar. 31, 2017	Dec. 31, 2016	Sep. 07, 2016	Apr. 19, 2016	Jan. 17, 2012
Debt Instrument [Line Items]
Debt discount liability, facility fee			$ 75,000
Warrant expiration period			7 years
Cash balance in accounts held with the lender				$ 10,432,000	$ 10,425,000
Approximated Amount of debt discount			$ 129,000
Fair value of warrants on the issue date			54,000
Debt discount liability, legal fees			30,000
First Amended SVB Loan Agreement [Member]
Debt Instrument [Line Items]
Interest only payment percentage		7.50%
Maturity date of the term loans				Oct. 01, 2018
First Amended SVB Loan Agreement [Member] \| First Tranche [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement		$ 10,000,000
First Amended SVB Loan Agreement [Member] \| First Tranche [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement		$ 20,000,000
Second Amended SVB Loan Agreement [Member]
Debt Instrument [Line Items]
Interest only payment percentage	7.50%
Maturity date of the term loans				Jul. 01, 2018
Second Amended SVB Loan Agreement [Member] \| Without Interest- Only Extension [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage				6.50%
Second Amended SVB Loan Agreement [Member] \| With Interest-Only Extension [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage				8.00%
Amended SVB Loan Agreement [Member]
Debt Instrument [Line Items]
Percentage of common stock pledged				100.00%
Fourth Amended SVB Loan Agreement [Member] \| Maximum [Member] \| TransEnterix Europe [Member]
Debt Instrument [Line Items]
Percentage of equity interest owned							65.00%
Fifth Amended SVB Loan Agreement [Member]
Debt Instrument [Line Items]
Cash balance in accounts held with the lender						$ 10,000,000
Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount liability, discount				$ 210,000
Debt issuance costs paid to lenders and third parties				371,000
Debt issuance cost				280,000
Debt unamortized balance				$ 76,000	$ 107,000
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Note issuance date				Jan. 17, 2012
Debt Instrument, redemption price amount			498,920
Debt discount liability, facility fee			$ 255,000
Issue of warrants to purchase shares of company's common stock								430,815

Restructuring - Additional Information (Detail) - Headcount, Discontinued Efforts and Cancellation of Contracts [Member] - SurgiBot System [Member] $ in Millions	1 Months Ended
	May 31, 2016 USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 5.7
Inventory write-down related to restructuring	2.6
Restructuring and other charges	3.1
Restructuring amount paid in cash	0.5
Employee severance costs	0.4
Restructuring and other charges related to cancellation of contracts	0.1
Restructuring and other charges related to other non-cash charges	2.6
Disposal of long-lived assets	1.0
Patents [Member]
Restructuring Cost And Reserve [Line Items]
Write-off of intellectual property	$ 1.6

Equity Line Financing, Controlled Equity Offering and Public Offering of Common Stock - Additional Information (Detail) - USD ($)				1 Months Ended		3 Months Ended		12 Months Ended	33 Months Ended
	Dec. 16, 2016	Feb. 09, 2016	Feb. 20, 2015	Apr. 26, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2016	Nov. 30, 2014	Jan. 31, 2014
Stockholders Equity Common Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs						$ 5,304,000	$ 31,391,000
Common stock, shares issued						123,629,689		115,781,030	115,781,030
Aggregate maximum value of designated securities										$ 100,000,000	$ 100,000,000
Increase in value of designated securities					$ 50,000,000
Gross proceeds from public offering of securities									$ 179,200,000
Proceeds from issuance of common stock from public offering, net of issuance costs									$ 168,800,000
Amount available for future financing of common stock						$ 37,800,000
ATM Offering [Member]
Stockholders Equity Common Stock [Line Items]
Amount available for future financing of common stock						$ 2,400,000
Lincoln Park Capital Fund, LLC [Member]
Stockholders Equity Common Stock [Line Items]
Right to sell common stock	25,000,000
Term to purchase number of shares						36 months
Stock issued, shares						3,972,741		300,000
Additional common stock shares issued on a pro rata basis	119,551
Gross proceeds						$ 5,304,000		$ 412,500
Proceeds from issuance of common stock, net of issuance costs						5,304,000		$ 392,500
Amount available for future financing of common stock						19,500,000
Lincoln Park Capital Fund, LLC [Member] \| Subsequent Event [Member]
Stockholders Equity Common Stock [Line Items]
Gross proceeds				$ 5,700,000
Cantor Fitzgerald & Co. [Member]
Stockholders Equity Common Stock [Line Items]
Gross proceeds		$ 25,000,000				$ 0
Proceeds from issuance of common stock, net of issuance costs		$ 24,000,000
Sale of common stock in an at-the-market offering		43,600,000	25,000,000
Percentage of commission paid		3.00%	3.00%
Common stock, shares issued		7,724,488
Maximum [Member] \| Lincoln Park Capital Fund, LLC [Member]
Stockholders Equity Common Stock [Line Items]
Right to direct to purchase number of shares	150,000
Obligation under regular purchase of shares	$ 2,000,000
Commitment Shares [Member] \| Lincoln Park Capital Fund, LLC [Member]
Stockholders Equity Common Stock [Line Items]
Stock issued, shares						345,421

Equity Line Financing, Controlled Equity Offering and Public Offering of Common Stock - Schedule of Total Sales under 2015 and 2016 Sales Agreement (Detail) - Cantor Fitzgerald & Co. [Member] - USD ($)		3 Months Ended	12 Months Ended
	Feb. 09, 2016	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Sale And Issue Of Shares Under Agreement [Line Items]
Gross proceeds	$ 25,000,000	$ 0
2016 Sales Agreement [Member]
Sale And Issue Of Shares Under Agreement [Line Items]
Total shares of common stock sold			8,763,400
Average price per share			$ 4.70
Gross proceeds			$ 41,156,000
Commissions earned by Cantor			1,235,000
Other issuance costs			$ 185,000
2015 Sales Agreement [Member]
Sale And Issue Of Shares Under Agreement [Line Items]
Total shares of common stock sold			5,710,200	2,014,300
Average price per share			$ 3.23	$ 3.25
Gross proceeds			$ 18,454,000	$ 6,546,000
Commissions earned by Cantor			$ 553,000	197,000
Other issuance costs				$ 259,000

Basic and Diluted Net Loss per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Basic And Diluted Earning Per Share [Abstract]
Adjustment to weighted average outstanding common shares	0	0

Related Person Transactions - Additional Information (Detail)					1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) shares	Jan. 04, 2017 EUR (€) shares	Dec. 30, 2016 EUR (€) shares	Sep. 21, 2015 shares	Nov. 30, 2016 EUR (€)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Jan. 04, 2017 $ / shares
Related Party Transaction [Line Items]
Fair value of contingent consideration \| $						$ 18,800,000		$ 22,800,000
Senhance Surgical Robotic System Acquisition [Member]
Related Party Transaction [Line Items]
Acquisition price \| €					€ 375,000
Reduction of contingent consideration \| $						1,227,000	$ 856,000
Common shares issued				15,543,413
Fair value of contingent consideration \| $	$ 18,800,000							$ 22,800,000
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member]
Related Party Transaction [Line Items]
Reduction of contingent consideration \| €			€ (5,000,000)
Common shares issued			3,722,685
Aggregate fair market value of common stock \| €			€ 5,000,000
Fair value of contingent consideration \| €		€ 5,000,000
Share price \| $ / shares									$ 1.404
Number of consecutive trading days		10 days
Common Stock [Member] \| Senhance Surgical Robotic System Acquisition [Member]
Related Party Transaction [Line Items]
Common shares issued	3,722,685
Common Stock [Member] \| Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member]
Related Party Transaction [Line Items]
Common shares issued			3,722,685
Sofar [Member]
Related Party Transaction [Line Items]
Expenses under service agreement with related party \| $						$ 52,000	$ 80,000
Sofar [Member] \| Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member]
Related Party Transaction [Line Items]
Common shares issued		3,722,685
Sofar [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	16.00%					16.00%	14.00%

Commitments and Contingencies - Additional Information (Detail) € in Millions					3 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) shares	Jan. 04, 2017 EUR (€)	Dec. 30, 2016 EUR (€) shares	Sep. 21, 2015 shares	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Operating Leased Assets [Line Items]
Fair value of contingent consideration \| $					$ 18,800,000		$ 22,800,000
Liability or related charge recorded for legal contingencies \| $	$ 0				0		0
Senhance Surgical Robotic System Acquisition [Member]
Operating Leased Assets [Line Items]
Contingent consideration related to acquisition \| $					$ 1,227,000	$ 856,000
Common shares issued \| shares				15,543,413
Fair value of contingent consideration \| $	$ 18,800,000						$ 22,800,000
Senhance Surgical Robotic System Acquisition [Member] \| Common Stock [Member]
Operating Leased Assets [Line Items]
Common shares issued \| shares	3,722,685
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member]
Operating Leased Assets [Line Items]
Contingent consideration related to acquisition \| €			€ (5.0)
Common shares issued \| shares			3,722,685
Aggregate fair market value of common stock \| €			€ 5.0
Fair value of contingent consideration \| €		€ 5.0
Senhance Surgical Robotic System Acquisition [Member] \| Second Tranche [Member] \| Common Stock [Member]
Operating Leased Assets [Line Items]
Common shares issued \| shares			3,722,685

Subsequent Events - Additional Information (Detail) - USD ($)				1 Months Ended	3 Months Ended	12 Months Ended
	May 10, 2017	Apr. 28, 2017	Sep. 26, 2014	Apr. 26, 2017	Mar. 31, 2017	Dec. 31, 2016	Jan. 17, 2012
Subsequent Event [Line Items]
Facility fee payment			$ 75,000
Warrants expiration period			7 years
Loan and Security Agreement [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares							430,815
Term loans issuance date					Jan. 17, 2012
Facility fee payment			$ 255,000
Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Gross proceeds					$ 5,304,000	$ 412,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares		24,900,000
Public offering price		$ 1.00
Gross proceeds from public offering		$ 24,900,000
Net proceeds from public offering		$ 23,200,000
Warrants exercised		0
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Term Loan [Member]
Subsequent Event [Line Items]
Warrants expiration period	5 years
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Term Loan [Member] \| First Tranche [Member]
Subsequent Event [Line Items]
Facility fee payment	$ 170,000
Warrants, exercise price	$ 1.00
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Term Loan [Member] \| First Tranche [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares	1,244,746
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Innovatus Life Sciences Lending Fund I, LP [Member] \| Term Loan [Member]
Subsequent Event [Line Items]
Term loans issuance date	May 10, 2017
Term loans aggregate principal amount	$ 17,000,000
Interest only payment period	24 months
Term loans maturity period	4 years
Repayment of term loans period	2 years
Debt instrument amortization schedule	24 months
Debt instrument repayment term	The interest-only period will end if the Company fails to meet any Interest-Only Milestone. Commencing on the first day of the month following such failure to achieve an Interest-Only Milestone, the Company will be required to repay the term loans over a two year period, based on a twenty-four (24) month amortization schedule.
Interest-only milestone terms	The Interest-Only Milestones require the Company to (i) achieve certain twelve month revenue targets, measured quarterly, commencing with quarter ending March 31, 2018, (ii) meet a minimum capital raising threshold through the sale and issuance of equity securities during the period from April 10, 2017 through May 31, 2018 and (iii) obtain clearance for commercialization of the Senhance System by the U.S. Food and Drug Administration (“Senhance Clearance”) by May 30, 2018 (each such milestone, an “Interest-Only Milestone”).
Term loans fixed interest rate	11.00%
Term loans fixed interest rate, paid in-kind percentage	2.50%
Term loans payment terms	The Company will be required to repay the term loans if they are accelerated following an event of default. In addition, the Company is permitted to prepay the term loans in full at any time upon five (5) business days’ written notice to the Lenders. Upon the earliest to occur of the maturity date, acceleration of the term loan, or prepayment of the term loan, the Company is required to make a final payment equal to the total term loan commitment multiplied by four percent (4%) (the “Final Fee”); provided, however, that in the event the Company refinances its obligations with the Lender after Senhance Clearance, no Final Fee or Prepayment Fee (as defined below) will be due thereunder ; and provided, further, that if the Company elects to refinance its obligations prior to the funding of the second tranche, the Final Fee with respect to the second tranche shall be paid in full on the date of such refinancing. Any prepayment of the term loans in full, whether mandatory or voluntary, must include (i) the Final Fee, (ii) interest at the default rate (which is the rate otherwise applicable plus five percent (5%)) with respect to any amounts past due, (iii) the Lenders’ expenses and all other obligations that are due and payable to the Lenders and (iv) a prepayment fee of three percent (3%) if the term loan is paid in full on or before the first anniversary of the effective date, two percent (2%) if paid off after the first anniversary but on or before the second anniversary of the effective date and one percent (1%) if paid off after the second anniversary but on or before the third anniversary of the effective date (the “Prepayment Fee”).
Term loans prepayment written notice period	5 days
Multiplier percentage of term loan commitment final fee payment	4.00%
Percentage of additional interest rate added to default rate	5.00%
Debt instrument covenant terms	Under the terms of the Innovatus Loan Agreement, the Company is required to maintain minimum unrestricted cash in an amount equal to (x) six million dollars ($6,000,000), at all times prior to Senhance Clearance; and (y) at all times thereafter, the least of (i) $6,000,000, (ii) the Company’s trailing three (3) months’ cash used to fund operating activities, as determined as of the most recent month end and (iii) the then outstanding principal amount of the term loans, together with accrued but unpaid interest.
Minimum unrestricted cash requirement prior to clearance	$ 6,000,000
Covenants unrestricted cash requirement amount	$ 6,000,000
Covenant measurement trailing period for cash operating activities	3 months
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Innovatus Life Sciences Lending Fund I, LP [Member] \| Term Loan [Member] \| On or Before First Anniversary of Effective Date [Member]
Subsequent Event [Line Items]
Prepayment fee percentage	3.00%
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Innovatus Life Sciences Lending Fund I, LP [Member] \| Term Loan [Member] \| After First Anniversary but on or Before Second Anniversary of the Effective Date [Member]
Subsequent Event [Line Items]
Prepayment fee percentage	2.00%
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Innovatus Life Sciences Lending Fund I, LP [Member] \| Term Loan [Member] \| After Second Anniversary but on or Before Third Anniversary of the Effective Date [Member]
Subsequent Event [Line Items]
Prepayment fee percentage	1.00%
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Innovatus Life Sciences Lending Fund I, LP [Member] \| Term Loan [Member] \| First Tranche [Member]
Subsequent Event [Line Items]
Term loans aggregate principal amount	$ 14,000,000
Subsequent Event [Member] \| Loan and Security Agreement [Member] \| Innovatus Life Sciences Lending Fund I, LP [Member] \| Term Loan [Member] \| Second Tranche [Member]
Subsequent Event [Line Items]
Term loans aggregate principal amount	$ 3,000,000
Subsequent Event [Member] \| Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Gross proceeds				$ 5,700,000
Subsequent Event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Number of common stock or warrants in each unit		1
Subsequent Event [Member] \| Common Stock [Member] \| Series A Warrant [Member]
Subsequent Event [Line Items]
Number of common stock or warrants in each unit		1
Subsequent Event [Member] \| Common Stock [Member] \| Series B Warrant [Member]
Subsequent Event [Line Items]
Number of common stock or warrants in each unit		0.75